Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 31.05.15
Views: 2161

Prof Guohong Han - Xijing Hospital, Fourth Military Medical University, Xi'an, China

Dr Han talks to ecancertv at ASCO 2015 about a multicentre retrospective study to evaluate the efficacy of combination therapy over transarterial chemoembolisation (TACE) alone.

The study compared the overall survival between patients with ≥ grade 2 sorafenib-related dermatologic adverse events in the combination therapy group and patients treated with TACE alone.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation